The FDA granted accelerated approval to amivantamab-vmjw for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
[Clinical Oncology News]
7753456
nan
items
1
apa
0
default
asc
1
162964
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/